Ventyx biosciences announces positive results from the phase 2 trial of vtx002 in patients with moderate-to-severely active ulcerative colitis

Vtx002 60 mg achieved the primary endpoint of clinical remission with a high rate of complete endoscopic remission both 30 mg and 60 mg doses of vtx002 demonstrated an excellent safety and tolerability profile ventyx to host conference call and webcast today at 4:30 pm et san diego, oct. 09, 2023 (globe newswire) -- ventyx biosciences, inc. (nasdaq: vtyx) (“ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced positive results from the phase 2 trial of vtx002, a novel oral s1p1 receptor modulator, in patients with moderate-to-severely active ulcerative colitis (uc). “we are very excited to share the positive phase 2 results for vtx002, which we believe establish vtx002 as a potential best-in-disease oral therapy for uc based on its combined efficacy and safety profile,” said raju mohan, ph.d.
VTYX Ratings Summary
VTYX Quant Ranking